Dr. Eric Furfine of Mosaic Biosciences on picking the right discovery route, catching liabilities before they get expensive, and getting the most from a CRO partner.
Aging is the biggest single risk factor for most chronic diseases, yet drug development still goes after them one at a time, and regulators do not treat aging itself as …
Over the past decade, BenchSci has been comprehensively collecting, decoding, harmonizing, and structuring insights from tens of millions of biomedical publications and datasets into a machine‑readable map of disease biology—an …
Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from the expansion of therapeutic indications and the identification of drug …
Scientific knowledge is expanding faster than at any point in human history, with PubMed indexing over 1.3 million new biomedical articles annually. In parallel, organizations implementing lab automation are generating …
As we approach 2025, the role of chemistry Contract Research Organizations (CROs) is undergoing profound transformation. Chemistry is no longer considered a commodity but an essential component in the discovery …
The global drug development landscape is bustling, with over 20,000 biotechs competing for investor attention. Now more than ever, having a decisive edge is crucial to bring the right molecule …
MEDSIR (Medica Scientia Innovation Research) is an international company, based in Barcelona and New Jersey, specializing in the design and management of innovative oncology clinical trials. Since its founding in …
In an industry as critical as clinical trials, where efficient data management and swift processes are paramount, outdated tech methods often create organizational barriers. Digital tools, data management systems, and …
Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving treatments for patients. Unfortunately, the success rate of clinical trials, …
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential …
In the realm of clinical trials, efficient data management and monitoring are crucial yet often hampered by outdated and time-consuming practices. This case study delves into the implementation of Trialize, …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.